Compare Merck & Co., Inc. (MRK) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Paycom Software Inc — how do they compare? Merck & Co., Inc. trades at $130.29 (market cap $323.00B), while Paycom Software Inc trades at $211 (market cap $9.62B). The key difference: Merck & Co., Inc. is far larger — about 33.6× Paycom Software Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| MRK | PAYC | |
|---|---|---|
Market Cap | $323.00B | $9.62B |
Sector | Health | Technology |
52-Week High | $131.84 | $233.89 |
52-Week Low | $77.60 | $113.59 |
Enterprise Value | $369.77B | $10.41B |
Dividend Yield | 2.6% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Paycom Software (PAYC) trades at $214.94, down 0.48% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong fundamentals, including a 22.78% net income margin and consistent earnings beats, most recently with Q2 2026 EPS of $2.78 versus $2.38 expected. Recent news highlights AI-driven demand and raised 2026 guidance, fueling positive sentiment.
Outlook remains favorable due to robust profitability and growth initiatives, though risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting modest upside potential from current levels amid balanced buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
